DENVER — National Jewish Health researchers are looking for ways to identify patients with untreated mild persistent asthma who might benefit from daily inhaled treatment based on inflammatory ...

ARLINGTON HEIGHTS, Ill. (April 15 , 2025) - Did you know about 24 million people in the United States have asthma, representing roughly 8% of the population? May is Asthma and Allergy Awareness Month, ...

Primatene Mist is the only OTC inhaler approved by the FDA for mild asthma in people 12 and older. Primatene Mist uses epinephrine, while albuterol uses albuterol sulfate, and they have different side ...

Asthma is a global issue. It's estimated that more than 334 million people around the world have asthma. It's a chronic disease that makes it hard to breathe. Asthma often starts in childhood, but can ...

The BATURA trial ended early due to high efficacy data at pre-planned analysis. Topline results were announced from a phase 3b trial evaluating albuterol/budesonide metered dose inhaler in patients ...

Adults who were taking dupilumab for their atopic dermatitis also experienced significant improvements in their mild asthma, primarily in the first 16 weeks, according to a study published in Clinical ...

Asthma might seem like one of those health conditions that is absolutely unmistakeable. It’s kind of obvious if you just...can’t really breathe, right? Actually, asthma symptoms can present with a lot ...

CHICAGO, May 16 (Reuters) - People whose mild asthma is under control may be able to safely step down to a daily treatment, researchers said on Wednesday. Sign up here. Current treatment guidelines ...

Learn about common asthma triggers, from dust mites to food allergens, that may be hiding in your child’s backpack, and ...

Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed. After receiving ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis AstraZeneca’s inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated ...